Free Trial

Athira Pharma (ATHA) Stock Price, News & Analysis

Athira Pharma logo
$0.43 +0.01 (+3.28%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.45 +0.01 (+2.81%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Athira Pharma Stock (NASDAQ:ATHA)

Key Stats

Today's Range
$0.41
$0.44
50-Day Range
$0.24
$0.43
52-Week Range
$0.22
$3.67
Volume
270,517 shs
Average Volume
1.59 million shs
Market Capitalization
$16.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25
Consensus Rating
Hold

Company Overview

Athira Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

ATHA MarketRank™: 

Athira Pharma scored higher than 76% of companies evaluated by MarketBeat, and ranked 511th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Athira Pharma has received no research coverage in the past 90 days.

  • Read more about Athira Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Athira Pharma has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Athira Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    3.94% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 10.81%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Athira Pharma does not currently pay a dividend.

  • Dividend Growth

    Athira Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.94% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 10.81%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Athira Pharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,743.00 in company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Athira Pharma's insider trading history.
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATHA Stock News Headlines

Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
Athira Pharma Inc.
See More Headlines

ATHA Stock Analysis - Frequently Asked Questions

Athira Pharma's stock was trading at $0.5867 at the beginning of 2025. Since then, ATHA stock has decreased by 25.9% and is now trading at $0.4348.

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings results on Friday, May, 9th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.03.

Athira Pharma (ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

Last Earnings
5/09/2025
Today
7/12/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHA
CIK
1620463
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$22.00
Low Price Target
$0.50
Potential Upside/Downside
+2,487.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-142.99%
Return on Assets
-106.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.26
Quick Ratio
7.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.16 per share
Price / Book
0.37

Miscellaneous

Outstanding Shares
39,040,000
Free Float
30,414,000
Market Cap
$16.97 million
Optionable
Optionable
Beta
2.99
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ATHA) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners